CC
BIIB icon

Capital Counsel’s Biogen BIIB Stock Holding History

Capital Counsel’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-825
Closed -$253K – 70
2015
Q4 		$253K Sell
825
-7
-0.8% -$2.01K 0.01% 115
2015
Q3 		$243K Sell
832
-50
-6% -$16.5K 0.01% 107
2015
Q2 		$356K Buy
882
+50
+6% +$20.1K 0.02% 101
2015
Q1 		$351K Sell
832
-34
-4% -$13.4K 0.02% 102
2014
Q4 		$294K Hold
866
– – 0.01% 110
2014
Q3 		$286K Hold
866
– – 0.02% 113
2014
Q2 		$273K Hold
866
– – 0.01% 117
2014
Q1 		$265K Hold
866
– – 0.01% 120
2013
Q4 		$242K Hold
866
– – 0.01% 131
2013
Q3 		$208K Buy
+866
New +$194K 0.01% 124

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Capital Counsel's BIIB Position: Q1 2016 in Review

Capital Counsel sold out of Biogen (BIIB) in Q1 2016, closing a stake of 825 shares — an estimated $253K sold.

Capital Counsel first reported a position in BIIB in Q3 2013 and held it in 10 quarters. The position peaked at $356K in Q2 2015. 948 funds tracked by Wall St. Rank hold BIIB as of Q1 2016.

  • Capital Counsel reported no remaining Biogen position as of Q1 2016 after selling out during the quarter.
  • Capital Counsel sold 825 Biogen shares in Q1 2016, an estimated $253K.
  • Capital Counsel first reported a position in Biogen in Q3 2013 and held it in 10 quarters.
  • Capital Counsel's Biogen position peaked at $356K in Q2 2015.
  • 948 funds tracked by Wall St. Rank held Biogen as of Q1 2016.

Based on Capital Counsel's 13F filing for Q1 2016, filed 13 May 2016.